INCLISIRAN: A SYSTEMATIC REVIEW OF THE BENEFITS OF PROMISING LIPID-LOWERING IN THE TREATMENT OF DYSLIPIDEMIAS (Atena Editora)

Registro completo de metadados
MetadadosDescriçãoIdioma
Autor(es): dc.contributor.authorSOUZA, AMANDA LIMA-
Autor(es): dc.contributor.authorPEREIRA, LORRAINE ROSSI-
Autor(es): dc.contributor.authorSOUZA, YORRANE MAXYME ALVES DE-
Autor(es): dc.contributor.authorSANQUITE, MICHEL DE OLIVEIRA-
Autor(es): dc.contributor.authorSAYED, YOUMNA AL-
Autor(es): dc.contributor.authorSPADOTO, LARA BELTRAME-
Autor(es): dc.contributor.authorBRUNEL, ALEX BRUNO VILHALBA-
Autor(es): dc.contributor.authorFILHO, ANTÔNIO ALVES DE MORAIS-
Autor(es): dc.contributor.authorJUNIOR, MARCELO ORIONE TOLENTINO LIMA-
Autor(es): dc.contributor.authorBEZERRA, REGINA KELLY DAVID-
Autor(es): dc.contributor.authorANDRADE, MARIA CAROLAINE QUEIROZ DE-
Data de aceite: dc.date.accessioned2022-12-22T13:27:08Z-
Data de disponibilização: dc.date.available2022-12-22T13:27:08Z-
Data de envio: dc.date.issued2022-10-20-
Fonte: dc.identifier.urihttp://educapes.capes.gov.br/handle/capes/718983-
Resumo: dc.description.abstractObjective: To evaluate the reduction of negative outcomes and increase in survival with the new lipid-lowering therapy on the market, as well as its superiority in relation to other drugs, having as a fundamental principle of management the reduction of LDL cholesterol levels. Methods: An integrative review was carried out, using as criteria the search in the National Library of Medicine (PubMed) and Scientific Electronic Library Online (SciELO) databases using the descriptors (i) inclisiran (ii) PCSK9, (iii) dyslipidemias with the Boolean operator “AND”. Studies published from 2018 to 2022 were included. Results: The approved inclisiran has been shown to reduce LDL cholesterol levels by more than 50%, it also brings as a positive point the factor of durability of the therapy, being proposed as a vaccine for patients with dyslipidemia, the which is an immeasurable advance in cardiology and endocrinology in recent years, not requiring daily doses of medication, which facilitates therapeutic adherence and the reduction of cardiovascular outcomes. With adverse effects, 4.69% of patients who received inclisiran reported an injection site reaction, all reactions were transient, there was no evidence of liver, kidney, muscle or platelet toxicity. Final considerations: PCSK9 inhibitors are a welcome addition to our approaches to reducing LDL-C and cardiovascular events in patients with high levels of dyslipidemia and refractory to conventional treatments.pt_BR
Idioma: dc.language.isoenpt_BR
Palavras-chave: dc.subjectDyslipidemiapt_BR
Título: dc.titleINCLISIRAN: A SYSTEMATIC REVIEW OF THE BENEFITS OF PROMISING LIPID-LOWERING IN THE TREATMENT OF DYSLIPIDEMIAS (Atena Editora)pt_BR
Tipo de arquivo: dc.typelivro digitalpt_BR
Aparece nas coleções:Livros digitais